Selecciona tu país
América
Argentina
Brasil
Canadá
Chile
Colombia
Costa Rica
Ecuador
El Salvador
Estados Unidos
México
Perú
República Dominicana
Uruguay
Europa
Alemania
Austria
Bélgica
Croacia
Dinamarca
Eslovaquia
Eslovenia
España
Finlandia
Francia
Grecia
Hungría
Irlanda
Italia
Letonia
Malta
Noruega
Países Bajos
Polonia
Portugal
Reino Unido
República Checa
Serbia
Suecia
Suiza
Resto del mundo


Sodium Glucose Transporter 2 Inhibitors (en Inglés)
Martin C. Michel (Autor) · Springer Nature Switzerland · Tapa Dura
Quedan 50 unidades
₡ 110.125Inhibitors of the sodium glucose transporter 2 (SGLT2) such as canagliflozin, dapagliflozin, or empagliflozin were primarily developed for the treatment of diabetes. Meanwhile, they have been game changers in the treatment of conditions such as heart failure and renal failure in both diabetic and non-diabetic patients. Importantly, they do not only improve disease-specific outcomes but even reduce overall mortality by about one third. Thus, they have become game changers for indications affecting millions of people. This volume discusses their efficacy and safety with emphasis on diabetes, heart failure and renal failure. Mechanistic insight from animal studies and potential additional uses are also being discussed.
¿Tienes una pregunta sobre el libro? Inicia sesión para poder agregar tu propia pregunta.


